https://scholars.lib.ntu.edu.tw/handle/123456789/470195
標題: | Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients | 作者: | SUNG-HSIN KUO HUANG-CHUN LIEN You S.-L. YEN-SHEN LU CHING-HUNG LIN Chen T.-Z. CHIUN-SHENG HUANG |
公開日期: | 2008 | 出版社: | Churchill Livingstone | 卷: | 17 | 期: | 6 | 起(迄)頁: | 646-653 | 來源出版物: | Breast | 摘要: | To assess the effect of a non-standard dose and regimen of adjuvant chemotherapy on the clinical outcome in stage I-II and operable stage III Taiwanese breast cancer patients. Variables studied included treatment variation (regimen and dose of adjuvant therapy), lymph node status, tumor size, histologic grade, and hormone receptor status. Cox's multivariate regression analyses were used to select prognostic factors significant for disease-free survival (DFS) and overall survival (OS). In the multivariate analysis, lymph node-positive, a tumor size greater than 5 cm, grade III, hormone receptor-negative status, and non-standard adjuvant chemotherapy were independent prognostic factors for DFS and/or OS. Node-positive patients treated with standard adjuvant chemotherapy had a significantly better DFS (HR = 0.6; P = 0.032) and OS (HR = 0.54; P = 0.025) than those treated with non-standard adjuvant chemotherapy. Breast cancer patients receiving standard adjuvant chemotherapy have a better DFS and OS than those receiving non-standard adjuvant chemotherapy. ? 2008 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-56749167950&doi=10.1016%2fj.breast.2008.05.006&partnerID=40&md5=90d336f6c3b550c013646c7f2fb24860 https://scholars.lib.ntu.edu.tw/handle/123456789/470195 |
ISSN: | 0960-9776 | DOI: | 10.1016/j.breast.2008.05.006 | SDG/關鍵字: | anthracycline derivative; antineoplastic agent; carboplatin; cisplatin; cyclophosphamide; doxorubicin; epirubicin; fluorouracil; hormone receptor; methotrexate; paclitaxel; recombinant granulocyte colony stimulating factor; thiotepa; adult; aged; article; breast cancer; breast carcinoma; cancer adjuvant therapy; cancer combination chemotherapy; cancer grading; cancer patient; cancer staging; cancer survival; controlled study; disease free survival; drug megadose; female; human; lymph node metastasis; major clinical study; multiple cycle treatment; optimal drug dose; overall survival; peripheral blood stem cell transplantation; priority journal; prognosis; repeated drug dose; stem cell mobilization; Taiwan; treatment outcome; tumor volume |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。